Mobile healthcare provider DocGo's Q4 revenue beats estimates

DocGo

16/03/2026 20:20

Overview

US mobile health services provider's Q4 revenue fell yr/yr but beat analyst expectations

Company launched formal process to explore strategic alternatives

Outlook

DocGo raises 2026 revenue guidance to $290-$310 mln, up from $280-$300 mln prior

Company now expects 2026 adj EBITDA loss of $5-$10 mln, improved from prior loss of $15-$25 mln

DocGo expects to achieve profitability in the second half of 2026

Result Drivers

MIGRANT PROGRAM WIND-DOWN - Revenue decline attributed to wind-down of migrant-related programs, which contributed $7.4 mln in Q4 2025 versus $60.2 mln in Q4 2024

CORE BUSINESS GROWTH - Excluding migrant-related programs, revenue rose 11% yr/yr, driven by growth in 'healthcare at any address' services and contribution from SteadyMD acquisition

IMPAIRMENT CHARGES - Net loss included $78 mln in non-cash impairments of intangible assets, goodwill, and an equity investment

Company press release: ID:nBw63yXjda

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$74.9 mln
$70.35 mln (6 Analysts)
Q4 EPS
-$1.84
Q4 Net Income
-$142.3 mln
Q4 Adjusted EBITDA
Miss
-$11.3 mln
-$9.70 mln (6 Analysts)
Q4 Gross Margin
27.2%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for DocGo Inc is $3.00, about 356.5% above its March 13 closing price of $0.66

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)